A primary-source-verifiable measurement
When FDA finds serious cGMP problems at a foreign drug facility, two things happen — but not at the same time. First, the firm is placed on Import Alert 66-40 (the “Red List”), and its shipments are detained at the US border under Detention Without Physical Examination. Weeks later, FDA may publish a warning letter. The market reacts to the warning letter. The border block is already in effect.
Flowchem Pharma Private Limited (Andhra Pradesh, India) was placed on Import Alert 66-40 on 2026-01-22. The FDA warning letter did not publish until 2026-03-11 — a 48-day gap, verifiable directly from the dates on FDA's own records, not a secondary estimate.
| Event | Date | Effect |
|---|---|---|
| Import Alert 66-40 placement (Red List) | 2026-01-22 | Shipments detained at the US border immediately |
| Warning letter published | 2026-03-11 | The signal the market usually waits for |
| Gap | 48 days | The lead time a Quality team can act in |
For a pharma Quality team that sources API or finished product from a foreign site, learning about a supplier's FDA trouble at the warning letter is learning about it 48 days late. The import-alert placement is the earlier, operationally-binding signal — but it sits in a 1.9 MB unsearchable FDA HTML page, siloed from MHRA and CDSCO. FlaggedRx resolves one supplier across those regulators and alerts you on the border flag. See the live, searchable Red List.
Both dates are taken from FDA's own records (the Import Alert 66-40 placement date and the warning-letter publication date). A single case is an existence proof, not a distribution — gaps vary by firm and by FDA's cadence, and warning letters do not always follow an import alert. We measure and cite; we don't extrapolate a fixed “average.” Absence of a flag on any firm is never an all-clear.